Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Here's Why Aurinia Pharmaceuticals Is Falling Today

TheMotleyFool

0 0

Here's Why Aurinia Pharmaceuticals Is Falling TodayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png

Aurinia Pharmaceuticals (NASDAQ: AUPH) stock has fallen sharply in response to a recent regulatory filing. Investors feeling queasy about the unlimited shelf registration statement that the company filed on Friday had pulled its share price down by 26.8% as of 10:49 a.m. ET Monday.

In January, the Food and Drug Administration approved Aurinia's first drug, Lupkynis, for the treatment of lupus nephritis. As is often the case when an independent drugmaker launches its first drug, sales of Lupkynis haven't lived up to expectations.

Image source: Getty Images.

Source Fool.com

Like: 0

AUPH

Teilen